Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

Company Overview

Intellipharmaceutics International Inc. was a Canadian specialty pharmaceutical company focused on developing oral drug-delivery technologies and pharmaceutical products. The company’s research centered on controlled-release, extended-release and targeted-release formulations intended to improve dosing convenience, therapeutic performance and medication safety.

Its development portfolio included generic and proprietary medicines, with an emphasis on central nervous system treatments and products designed to address unmet medical needs. Historical pipeline programs included abuse-deterrent opioid formulations such as Rexista and SequestOx, as well as other extended-release pharmaceutical products. Intellipharmaceutics pursued regulatory approvals in the United States and Canada and sought licensing and commercialization arrangements for its products.

Founded in 1998 and based in Toronto, Ontario, Intellipharmaceutics operated primarily as a research and development pharmaceutical company rather than a large-scale commercial drug manufacturer. Public records indicate that the company encountered significant financial and operating difficulties in the late 2010s and subsequently discontinued active operations. Current information about its management, commercial activities and product availability is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 12,042 shs
• Market Capitalization: $4.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 7/16/2018
• Today: 9/24/2026
• Fiscal Year End: 11/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:IPCIF
• CIK: 1474835
• Web: www.intellipharmaceutics.com
• Phone: 416-798-3001
• Fax: 416-798-3007
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $660 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.32) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,093,000
• Free Float: 32,511,000
• Market Cap: $4.96 million
• Optionable: Not Optionable
• Beta: 1.53